About the Company
Vallon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company, headquartered in Philadelphia, PA. The Company is focused on the development of new medications to help patients with central nervous system (CNS) disorders. The Company’s lead investigational product candidate, ADAIR, is a novel abuse deterrent formulation of amphetamine immediate release being developed for the treatment of ADHD and narcolepsy.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $VLON News
Cancer Focused Micro-Cap Xilio Therapeutics Stock Doubles In One Session - Here's Why
Xilio Therapeutics Inc (NASDAQ:XLO) shares are surging as the company announced an exclusive license agreement with Gilead ...
Analyst Issues Sell Rating for Vertex Pharmaceuticals Amid Intensifying Drug Market Competition
Whitney Ijem, an analyst from Canaccord Genuity, maintained the Sell rating on Vertex Pharmaceuticals (VRTX – Research Report). The ...
Loading the latest forecasts...